JP2023513434A5 - - Google Patents

Info

Publication number
JP2023513434A5
JP2023513434A5 JP2022545028A JP2022545028A JP2023513434A5 JP 2023513434 A5 JP2023513434 A5 JP 2023513434A5 JP 2022545028 A JP2022545028 A JP 2022545028A JP 2022545028 A JP2022545028 A JP 2022545028A JP 2023513434 A5 JP2023513434 A5 JP 2023513434A5
Authority
JP
Japan
Prior art keywords
cells
car
seq
expressing
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022545028A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513434A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/014775 external-priority patent/WO2021151008A1/en
Publication of JP2023513434A publication Critical patent/JP2023513434A/ja
Publication of JP2023513434A5 publication Critical patent/JP2023513434A5/ja
Pending legal-status Critical Current

Links

JP2022545028A 2020-01-24 2021-01-22 養子細胞療法における投与ならびに濾胞性リンパ腫および辺縁帯リンパ腫の処置のための方法 Pending JP2023513434A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062965774P 2020-01-24 2020-01-24
US62/965,774 2020-01-24
US202063037542P 2020-06-10 2020-06-10
US63/037,542 2020-06-10
US202063068975P 2020-08-21 2020-08-21
US63/068,975 2020-08-21
PCT/US2021/014775 WO2021151008A1 (en) 2020-01-24 2021-01-22 Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy

Publications (2)

Publication Number Publication Date
JP2023513434A JP2023513434A (ja) 2023-03-31
JP2023513434A5 true JP2023513434A5 (OSRAM) 2024-01-31

Family

ID=74673319

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022545028A Pending JP2023513434A (ja) 2020-01-24 2021-01-22 養子細胞療法における投与ならびに濾胞性リンパ腫および辺縁帯リンパ腫の処置のための方法

Country Status (10)

Country Link
US (1) US20230071910A1 (OSRAM)
EP (1) EP4093433A1 (OSRAM)
JP (1) JP2023513434A (OSRAM)
KR (1) KR20220145341A (OSRAM)
CN (1) CN115315269A (OSRAM)
AU (1) AU2021209940A1 (OSRAM)
BR (1) BR112022014501A2 (OSRAM)
IL (1) IL294724A (OSRAM)
MX (1) MX2022009041A (OSRAM)
WO (1) WO2021151008A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111225675B (zh) 2017-06-02 2024-05-03 朱诺治疗学股份有限公司 使用过继细胞疗法治疗的制品和方法
MA50855A (fr) 2017-11-01 2020-09-09 Juno Therapeutics Inc Procédé de génération de compositions thérapeutiques de cellules modifiées
CN116287235A (zh) * 2022-12-01 2023-06-23 天津金域医学检验实验室有限公司 一种检测边缘区淋巴瘤疑似患者的荧光原位杂交-荧光定量pcr技术产品及试剂盒和系统

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
AU6467796A (en) 1996-04-24 1997-05-15 Claude Fell Cell separation system for biological fluids like blood
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
CN1182882C (zh) 1998-12-24 2005-01-05 生物安全股份有限公司 特别用于浓缩造血干细胞的血液分离系统
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
ES2345837T3 (es) 2005-03-23 2010-10-04 Biosafe S.A. Sistema integrado para la recogida, el procesamiento y el trasplante de subgrupos de celulas, incluyendo celulas madre adultas, para medicina regenerativa.
PL2856876T3 (pl) 2007-03-30 2018-06-29 Memorial Sloan-Kettering Cancer Center Konstytutywna ekspresja ligandów kostymulujących na limfocytach T poddanych transferowi adoptywnemu
ES2640216T3 (es) 2007-12-07 2017-11-02 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
TR201802323T4 (tr) 2007-12-11 2018-03-21 Univ North Carolina Chapel Hill Polipürin yolu modifiye edilmiş retroviral vektörler.
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
ES2717629T3 (es) 2009-11-03 2019-06-24 Hope City Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
US10208086B2 (en) 2011-11-11 2019-02-19 Fred Hutchinson Cancer Research Center Cyclin A1-targeted T-cell immunotherapy for cancer
EP3594245A1 (en) 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
CN107557334B (zh) 2012-05-03 2021-06-25 弗雷德哈钦森癌症研究中心 增强亲和力的t细胞受体及其制备方法
PL3824905T3 (pl) 2012-08-20 2025-05-05 Fred Hutchinson Cancer Center Sposób i kompozycje do immunoterapii komórkowej
SG11201502598SA (en) 2012-10-02 2015-05-28 Sloan Kettering Inst Cancer Compositions and methods for immunotherapy
JP5372297B1 (ja) 2012-12-20 2013-12-18 三菱電機株式会社 車載装置及びプログラム
WO2014190273A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
AU2014368892B2 (en) 2013-12-20 2019-06-13 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
IL313845A (en) 2014-04-23 2024-08-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
CN113736828A (zh) 2014-11-05 2021-12-03 朱诺治疗学股份有限公司 用于转导及细胞处理的方法
IL255887B (en) * 2015-05-28 2022-09-01 Kite Pharma Inc Methods for training patients for t-cell therapy
CN107921064A (zh) * 2015-05-28 2018-04-17 凯德药业股份有限公司 用于t细胞疗法的诊断方法
MX2018014911A (es) * 2016-06-06 2019-08-12 Juno Therapeutics Inc Metodos para el tratamiento de afecciones malignas de celulas t usando terapia de celulas adoptivas.
MA50855A (fr) 2017-11-01 2020-09-09 Juno Therapeutics Inc Procédé de génération de compositions thérapeutiques de cellules modifiées
JP7410877B2 (ja) * 2018-05-03 2024-01-10 ジュノー セラピューティクス インコーポレイテッド キメラ抗原受容体(car)t細胞療法とキナーゼ阻害剤の併用療法

Similar Documents

Publication Publication Date Title
US12622954B2 (en) Anti-ICOS agonist antibodies and uses thereof
DK1976886T3 (en) Means and methods for the treatment of tumor diseases
FI3886875T3 (fi) Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä
US11591406B2 (en) Treatment for multiple myeloma (MM)
US20260116971A1 (en) Antibodies specific to human nectin-2
JP6184952B2 (ja) 抗cd19抗体とナイトロゲンマスタードとの併用療法
JP2021512107A5 (OSRAM)
AU2004308749A1 (en) CD40 antibody formulation and methods
AU2025203436A1 (en) Treatment paradigm for an anti-CD19 antibody and venetoclax combination treatment
JP2022513062A5 (OSRAM)
JP2014525926A5 (OSRAM)
US20250340634A1 (en) Dosage regimens for anti-cd19 agents and uses thereof
JP7712925B2 (ja) 腫瘍治療のための二重特異性融合タンパク質と抗Her2抗体の組合せ
JP2023547506A5 (OSRAM)
JP2025175307A (ja) 逐次抗cd19治療
CA3159534A1 (en) Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
CA3206413A1 (en) Antibodies against cd112r and uses thereof
JP2023540618A5 (OSRAM)
RU2023130537A (ru) Введение доз для лечения биспецифическим антителом к cd20/cd3
JP2024540320A5 (OSRAM)
EA048837B1 (ru) Ступенчатая анти-cd19 терапия